2022 Pharmacy Survey Results: Biosimilars | Part 3
Two-thirds of the respondents to our 2022 annual Pharmacy Survey believe that biosimilars will have a significant effect on drugs prices over the next several years.
Third of six parts
The Inflation Reduction Act may have thrown a wrench in the works. But otherwise, there is some momentum building for biosimilars. Thirty-seven biosimilars have been approved by the FDA and 22 are launched, according to our colleagues at Center for Biosimilars.® Next year may be something of a breakthrough, with a number of biosimilars to Humira (adalimumab) schedule to come on the market next year.
By a 2-to-1 ratio, respondents to our 2022 Pharmacy Survey see biosimilars as having their intended effect: 66% indicated that they believe biosimilars will have a significant effect on drug expenditures over the next several compared to just 25% who didn’t (9% had no opinion).
At the same time, a similar proportion (65%) agreed that lawmakers and regulators need to take steps to end the “patent thickets” — taking out many patents on a drug — that keep biosimilars off the market.
Many observers of the industry believe that interchangeability, the easy substitution of biosimilars for brand-name reference products, is important to the commercial and clinical success of biosimilars. Roughly a third (36%) of the respondents to our survey said interchangeability is important and 41% said it was somewhat important.
The survey had more than 950 respondents. It was distributed by Managed Healthcare Executive® and Pharmacy Times® in late June and early July. A large percentage of the respondents (38%) indicated that they work for pharmacy benefit managers.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More
